DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,615,349 B2 Riker Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,615,349 B2 Riker Et Al US007615349B2 (12) United States Patent (10) Patent No.: US 7,615,349 B2 Riker et al. (45) Date of Patent: Nov. 10, 2009 (54) MELANOMA GENESIGNATURE Barrow et al., “Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage.” Clin. Can. Res., vol. 12:764-771 (75) Inventors: Adam I. Riker, Mobile, AL (US); (2006). Steven Alan Enkemann, Lutz, FL (US) Bauskin et al., “Role of Macrophage Inhibitory Cytokine-1 in Tumorigenesis and Diagnosis of Cancer. Cancer Research, vol. (73) Assignees: H. Lee Moffitt Cancer Center and 66:4983-4986 (2006). Research Institute, Inc., Tampa, FL Baylin et al., “Alterations in DNA Methylation: A Fundamental (US); University of South Florida, Aspect of Neoplasia.” Adv. in Cancer Res, vol. 72: 141-196 (1998). Tampa, FL (US) Bittner et al., “Molecular classification of cutaneous malignant mela noma by gene expression profiling.” Nature, vol. 406:536-540 (*) Notice: Subject to any disclaimer, the term of this (2000). patent is extended or adjusted under 35 Brasseur et al. “Expression of Mage Genes in Primary and Metastatic U.S.C. 154(b) by 0 days. Cutaneous Melanoma.” Int. J. Cancer, vol. 63:375-380 (1995). Cascinelli et al., “Sentinel Lymph Node Biopsy in Cutaneous Mela (21) Appl. No.: 11/852,102 noma: The WHO Melanoma Program Experience.” Annals of Surgi cal Oncology, vol. 7:469-474 (2000). (22) Filed: Sep. 7, 2007 Chen et al., “Decreased PITX1 homeobox gene expression in human lung cancer.” Lung Cancer, vol. 55:287-294 (2007). (65) Prior Publication Data Coppola et al., “Correlation of Osteopontin Protein Expression and US 2008/O113360A1 May 15, 2008 Pathological Stage across a Wide Variety of Tumor Histologies.” Clin. Can. Res., vol. 10:184-190 (2004). Related U.S. Application Data DeRisi et al., “Use of a cDNA microarray to analyze gene expression patterns in human cancer.” Nature Genetics, vol. 14:457-460 (1996). (60) Provisional application No. 60/824,849, filed on Sep. Dobbin et al., “Interlaboratory Comparability Study of Cancer Gene 7, 2006. Expression Analysis Using Oligonucleotide Microarrays.” Clinical Cancer Research, vol. 11:565-572 (2005). (51) Int. Cl. Eton et al., “Prognostic Factors for Survival of Patients Treated CI2O I/68 (2006.01) Systemically for Disseminated Melanoma.” Journal of Clinical (52) U.S. Cl. .......................................................... 435/6 Oncology, vol. 16:1103-1111 (1998). (58) Field of Classification Search ...................... 435/6 Fujiwara et al., “Isolation of a candidate tumor Suppressor gene on See application file for complete search history. chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene.” Oncogene, vol. 10:891-895 (56) References Cited (1995). Gallagher et al., “Multiple markers for melanoma progression regu U.S. PATENT DOCUMENTS lated by DNA methylation: Insights from transcriptomic studies.” 7,056,674 B2 6, 2006 Baker et al. Carcinogenesis, vol. 26:1856-1867 (2005). 7,081,340 B2 7/2006 Baker et al. Garraway et al., “Integrative genomic anlayses identify MITF as a 7,171,311 B2 1/2007 Dai et al. lineage Survival oncogene amplified in malignant melanoma.” 7,247.426 B2 7/2007 Yakhini et al. Nature, vol. 436:117-122 (2005). 2006, O183141 A1 8/2006 Change et al. Golub et al., “Molecular Classification of Cancer: Class Discovery 2007/O154889 A1 7/2007 Wang et al. and Class Prediction by Gene Expression Monitoring.” Science, vol. 286:531-537 (1999). Haddad et al., “The Progression of Melanoma Nodal Metastasis is OTHER PUBLICATIONS Dependent on Tumor Thickness of the Primary Lesion.” Annals of Surgical Oncology, vol. 6: 144-149 (1999). Tockman et al (Cancer Res., 1992, 52:271 1s-2718s).* Hanahan et al., “The Hallmarks of Cancer. Cell, vol. 100:57-70 Greenbaum et al. (Genome Biology, 2003, vol. 4, Issue 9, pp. 117.1- (2000). 117.8).* Haqq et al., “The gene expression signatures of melanoma progres Glas et al., "Converting a breast cancer microarray signature into a sion.” Proc. Natl. Acad. Sci. U. S. A., vol. 102:6092-6097 (2005). high-throughput diagnostic test.” BMC Genomics, vol. 7:278-288 Harbig et al., “A sequence-based identification of the genes detected (2006). by probesets on the Affymetrix U133 plus 2.0 array.” Nucleic Acids Ai et al., “Epigenetic Silencing of the Tumor Suppressor Cystatin M Occurs during Breast Cancer Progression.” Cancer Research, vol. Research, vol. 33.e31 (2005). 66:7900-7909 (2006). (Continued) An et al., “Deletion of tumor Suppressor genes in Chinese non-Small cell lung cancer.” Cancer Letters, vol. 184:189-195 (2002). Primary Examiner Sean E Aeder Balch et al. “A New American Joint Committee on Cancer Staging (74) Attorney, Agent, or Firm Fish & Richardson P.C. System for Cutaneous Melanoma.” Cancer, vol. 88: 1484-1491 (2000). (57) ABSTRACT Balch et al., “Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma.” Journal of Clini cal Oncology, vol 19:3635-3648 (2001). Methods and compositions for evaluating gene expression in Balch et al., “Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer melanoma samples are provided herein. Melanoma Staging System.” Joint of Clinical Oncology, vol. 19:3622-3634 (2001). 8 Claims, 6 Drawing Sheets US 7,615,349 B2 Page 2 OTHER PUBLICATIONS Warrington et al., “Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes.” Physiol. Herman et al., “Gene Silencing in Cancer in Association with Pro Genomics, vol. 2: 143-147 (2000). moter Hypermethylation.” N. Engl. J. Med., vol. 349:2042-2054 Weyers et al., “Classification of Cutaneous Malignant Melanoma: A (2003). Reassessment of Histopathologic Criteria for the Distinction of Dif Hodi. “Well-DefinedMelanoma Antigens as Progression Markers for ferentTypes.” Cancer, vol. 86:288-299 (1999). Melanoma: Insights into Differential Expression and Host Response Winnepenninckx et al., “Gene Expression Profiling of Primary Cuta Based on Stage.” Clin. Can. Res., vol. 12:673-678 (2006). neous Melanoma and Clinical Outcome,” J. Natl. Cancer Inst., vol. Jaeger et al., “Gene Expression Signatures for Tumor Progression, 98:472-482 (2006). Tumor Subtype, and Tumor Thickness in Laser-Microdissected Wollmann et al., “The macrophage inhibitory cytokine integrates Melanoma Tissues.” Clin. Can. Res., vol. 13:806-815 (2007). AKT/PKB and MAP kinase signaling pathways in breast cancer Jemal et al., "Cancer Statistics, 2007, C.A. Cancer J. Clin., vol. cells.” Carcinogenesis, vol. 26:900-907 (2005). 57:43-66 (2007). Zhang et al., “Aberrant promoter methylation and silencing of the Jensen et al., “Down-Regulation of Pro-Apoptotic Genes is an Early POU2F3 gene in cervical cancer.” Oncogene, vol. 25:5436-5445 Event in the Progression of Malignant Melanoma.” Annals of Surgi (2006). cal Oncology, vol. 14:1416-1423 (2007). Zhou et al., “Osteopontin Expression Correlates with Melanoma Kim et al., “Epigenomic Profiling Reveals Novel and Frequent Tar Invasion.” J. Invest. Dermatol., vol. 124:1044-1052 (2005). gets of Aberrant DNA Methylation-Mediated Silencing in Malignant Alonso et al., “A High-Throughput Study in Melanoma Identifies Glioma.” Cancer Res., vol. 66:7490-7501 (2006). Epithelial-Mesenchymal Transition as a Major Determinant of Kolfschoten et al., “A genetic screen identifies PITX1 as a suppressor Metastasis.” Cancer Research, vol. 67:3450-3460 (2007). of RAS activity and tumorigenicity.” Cell, vol. 121:849-858 (2005). Baldi et al., “Identification of genes down-regulated during mela Lerebours et al., “Fine Deletion Mapping of Chromosome 8p in noma progression: a cDNA array study.” Experimental Dermatology, Non-Small-Cell Lung Carcinoma.” Int. J. Cancer, vol. 81:854-858 vol. 12:213-218 (2003). (1999). Becker et al., “Discrimination of Melanocytic Tumors by cDNA Levy et al., “MITF. master regulator of melanocyte development and Array Hybridization of Tissues Prepared by Laser Pressure Catapult melanoma oncogene.” Trends Molecular Medicine, vol. 12:406-414 ing.” The Journal of Investigative Dermatology, vol. 122:361-368 (2006). (2004). Li et al., “Model-based analysis of oligunucleotide arrays: Expres De Wit et al., “Analysis of differential gene expression in human sion index computation and outlier detection.” Proc. Natl. Acad. Sci. melanocytic tumour lesions by custom made oligonucleotide arrays.” U.S.A., vol. 98:31-36 (2001). British Journal of Cancer, vol. 92:2249-2261 (2005). Lord et al... “Increased CDX2 and decreased PITXI homeobox gene Dooley et al., “DNA Microarrays and Likelihood Ratio expression in Barrett's esophagus and Barrett’s-associated Bioinformatic Methods: Discovery of Human Melanocyte Biomark adenocarcinoma.” Surgery, vol. 138:924-931 (2005). ers.” Pigment Cell Res., vol. 16:245-253 (2003). McGill et al., “c-Met Expression is Regulated by Mitf in the Eisen et al., "Cluster analysis and display of genome-wide expression Melanocyte Lineage.” J. Biol. Chem., vol. 281: 10365-10373 (2006). patters.” Proc. Nat. Acad. Sci. USA, vol.95:14863-14868 (1998). Momparler, “Cancer epigenetics.” Oncogene, vol. 22:6479-6483 Felicetti et al., “Role of PLZF in melanoma progression.” Oncogene, (2003). vol. 23:4567-4576 (2004). Muthusamy et al., “Epigenetic Silencing of Novel Tumor Suppres Ghosh et al., “Three-Dimensional Culture of Melanoma Cells Pro sors in Malignant Melanoma.” Cancer Res., vol. 66:11187-11 193 foundly Affects Gene Expression Profile: A High Density (2006). Oligonucleotide Array Study,” Journal of Cellular Physiology, vol. Riker, “Isolation and Culture of Melanoma Cell Lines. Cancer Cell 204:522-531 (2005). Culture. Methods and Protocols, Totowa: Humana Press, vol. 88: 93 Heyer et al., “Exploring Expression Data: Identification and Analysis 100 (2004). of Coexpressed Genes' Genome Research, vol. 9:1106-1115 (1999). Riker et al., Development and Characterization of Melanoma Cell Hoek et al., “Expression Profiling Reveals Novel Pathways in the Lines Established by Fine Needle Aspiration Biopsy: Advances in the Transformation of Melanocytes to Melanomas.” Cancer Research, Monitoring of Patients with Metastatic Melanoma, Cancer Detection vol.
Load more

Recommended publications
  • RNA Expression Patterns in Serum Microvesicles from Patients With
    Noerholm et al. BMC Cancer 2012, 12:22 http://www.biomedcentral.com/1471-2407/12/22 RESEARCHARTICLE Open Access RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls Mikkel Noerholm1,2*, Leonora Balaj1, Tobias Limperg1,3, Afshin Salehi1,4, Lin Dan Zhu1, Fred H Hochberg1, Xandra O Breakefield1, Bob S Carter1,4 and Johan Skog1,2 Abstract Background: RNA from exosomes and other microvesicles contain transcripts of tumour origin. In this study we sought to identify biomarkers of glioblastoma multiforme in microvesicle RNA from serum of affected patients. Methods: Microvesicle RNA from serum from patients with de-novo primary glioblastoma multiforme (N = 9) and normal controls (N = 7) were analyzed by microarray analysis. Samples were collected according to protocols approved by the Institutional Review Board. Differential expressions were validated by qRT-PCR in a separate set of samples (N = 10 in both groups). Results: Expression profiles of microvesicle RNA correctly separated individuals in two groups by unsupervised clustering. The most significant differences pertained to down-regulated genes (121 genes > 2-fold down) in the glioblastoma multiforme patient microvesicle RNA, validated by qRT-PCR on several genes. Overall, yields of microvesicle RNA from patients was higher than from normal controls, but the additional RNA was primarily of size < 500 nt. Gene ontology of the down-regulated genes indicated these are coding for ribosomal proteins and genes related to ribosome production. Conclusions: Serum microvesicle RNA from patients with glioblastoma multiforme has significantly down- regulated levels of RNAs coding for ribosome production, compared to normal healthy controls, but a large overabundance of RNA of unknown origin with size < 500 nt.
    [Show full text]
  • PLATFORM ABSTRACTS Abstract Abstract Numbers Numbers Tuesday, November 6 41
    American Society of Human Genetics 62nd Annual Meeting November 6–10, 2012 San Francisco, California PLATFORM ABSTRACTS Abstract Abstract Numbers Numbers Tuesday, November 6 41. Genes Underlying Neurological Disease Room 134 #196–#204 2. 4:30–6:30pm: Plenary Abstract 42. Cancer Genetics III: Common Presentations Hall D #1–#6 Variants Ballroom 104 #205–#213 43. Genetics of Craniofacial and Wednesday, November 7 Musculoskeletal Disorders Room 124 #214–#222 10:30am–12:45 pm: Concurrent Platform Session A (11–19): 44. Tools for Phenotype Analysis Room 132 #223–#231 11. Genetics of Autism Spectrum 45. Therapy of Genetic Disorders Room 130 #232–#240 Disorders Hall D #7–#15 46. Pharmacogenetics: From Discovery 12. New Methods for Big Data Ballroom 103 #16–#24 to Implementation Room 123 #241–#249 13. Cancer Genetics I: Rare Variants Room 135 #25–#33 14. Quantitation and Measurement of Friday, November 9 Regulatory Oversight by the Cell Room 134 #34–#42 8:00am–10:15am: Concurrent Platform Session D (47–55): 15. New Loci for Obesity, Diabetes, and 47. Structural and Regulatory Genomic Related Traits Ballroom 104 #43–#51 Variation Hall D #250–#258 16. Neuromuscular Disease and 48. Neuropsychiatric Disorders Ballroom 103 #259–#267 Deafness Room 124 #52–#60 49. Common Variants, Rare Variants, 17. Chromosomes and Disease Room 132 #61–#69 and Everything in-Between Room 135 #268–#276 18. Prenatal and Perinatal Genetics Room 130 #70–#78 50. Population Genetics Genome-Wide Room 134 #277–#285 19. Vascular and Congenital Heart 51. Endless Forms Most Beautiful: Disease Room 123 #79–#87 Variant Discovery in Genomic Data Ballroom 104 #286–#294 52.
    [Show full text]
  • Supplemental Table S1
    Entrez Gene Symbol Gene Name Affymetrix EST Glomchip SAGE Stanford Literature HPA confirmed Gene ID Profiling profiling Profiling Profiling array profiling confirmed 1 2 A2M alpha-2-macroglobulin 0 0 0 1 0 2 10347 ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 1 0 0 0 0 3 10350 ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 1 0 0 0 0 4 10057 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1 0 0 0 0 5 10060 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1 0 0 0 0 6 79575 ABHD8 abhydrolase domain containing 8 1 0 0 0 0 7 51225 ABI3 ABI gene family, member 3 1 0 1 0 0 8 29 ABR active BCR-related gene 1 0 0 0 0 9 25841 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 1 0 1 0 0 10 30 ACAA1 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiol 0 1 0 0 0 11 43 ACHE acetylcholinesterase (Yt blood group) 1 0 0 0 0 12 58 ACTA1 actin, alpha 1, skeletal muscle 0 1 0 0 0 13 60 ACTB actin, beta 01000 1 14 71 ACTG1 actin, gamma 1 0 1 0 0 0 15 81 ACTN4 actinin, alpha 4 0 0 1 1 1 10700177 16 10096 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0 1 0 0 0 17 94 ACVRL1 activin A receptor type II-like 1 1 0 1 0 0 18 8038 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 1 0 0 0 0 19 8751 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 1 0 0 0 0 20 8728 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 1 0 0 0 0 21 81792 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 1 0 0 0 0 22 9507 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1
    [Show full text]
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • Mass Spectrometry-Based Proteomics Techniques and Their Application in Ovarian Cancer Research Agata Swiatly, Szymon Plewa, Jan Matysiak and Zenon J
    Swiatly et al. Journal of Ovarian Research (2018) 11:88 https://doi.org/10.1186/s13048-018-0460-6 REVIEW Open Access Mass spectrometry-based proteomics techniques and their application in ovarian cancer research Agata Swiatly, Szymon Plewa, Jan Matysiak and Zenon J. Kokot* Abstract Ovarian cancer has emerged as one of the leading cause of gynecological malignancies. So far, the measurement of CA125 and HE4 concentrations in blood and transvaginal ultrasound examination are essential ovarian cancer diagnostic methods. However, their sensitivity and specificity are still not sufficient to detect disease at the early stage. Moreover, applied treatment may appear to be ineffective due to drug-resistance. Because of a high mortality rate of ovarian cancer, there is a pressing need to develop innovative strategies leading to a full understanding of complicated molecular pathways related to cancerogenesis. Recent studies have shown the great potential of clinical proteomics in the characterization of many diseases, including ovarian cancer. Therefore, in this review, we summarized achievements of proteomics in ovarian cancer management. Since the development of mass spectrometry has caused a breakthrough in systems biology, we decided to focus on studies based on this technique. According to PubMed engine, in the years 2008–2010 the number of studies concerning OC proteomics was increasing, and since 2010 it has reached a plateau. Proteomics as a rapidly evolving branch of science may be essential in novel biomarkers discovery, therapy decisions, progression predication, monitoring of drug response or resistance. Despite the fact that proteomics has many to offer, we also discussed some limitations occur in ovarian cancer studies.
    [Show full text]
  • Comparison of Gene Expression Profiles in Chromate Transformed BEAS-2B Cells
    Comparison of Gene Expression Profiles in Chromate Transformed BEAS-2B Cells Hong Sun1, Harriet A. Clancy1, Thomas Kluz1, Jiri Zavadil2, Max Costa1* 1 Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York, United States of America, 2 Department of Pathology, NYU Cancer Institute and Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, New York, United States of America Abstract Background: Hexavalent chromium [Cr(VI)] is a potent human carcinogen. Occupational exposure has been associated with increased risk of respiratory cancer. Multiple mechanisms have been shown to contribute to Cr(VI) induced carcinogenesis, including DNA damage, genomic instability, and epigenetic modulation, however, the molecular mechanism and downstream genes mediating chromium’s carcinogenicity remain to be elucidated. Methods/Results: We established chromate transformed cell lines by chronic exposure of normal human bronchial epithelial BEAS-2B cells to low doses of Cr(VI) followed by anchorage-independent growth. These transformed cell lines not only exhibited consistent morphological changes but also acquired altered and distinct gene expression patterns compared with normal BEAS-2B cells and control cell lines (untreated) that arose spontaneously in soft agar. Interestingly, the gene expression profiles of six Cr(VI) transformed cell lines were remarkably similar to each other yet differed significantly from that of either control cell lines or normal BEAS-2B cells. A total of 409 differentially expressed genes were identified in Cr(VI) transformed cells compared to control cells. Genes related to cell-to-cell junction were upregulated in all Cr(VI) transformed cells, while genes associated with the interaction between cells and their extracellular matrices were down-regulated.
    [Show full text]
  • Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy
    Author Manuscript Published OnlineFirst on February 13, 2017; DOI: 10.1158/1078-0432.CCR-17-0270 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Transcriptional mechanisms of resistance to anti-PD-1 therapy Maria L. Ascierto1, Alvin Makohon-Moore2, 11, Evan J. Lipson1, Janis M. Taube3,4, Tracee L. McMiller5, Alan E. Berger6, Jinshui Fan6, Genevieve J. Kaunitz3, Tricia R. Cottrell4, Zachary A. Kohutek7, Alexander Favorov8,10, Vladimir Makarov7,11, Nadeem Riaz7,11, Timothy A. Chan7,11, Leslie Cope8, Ralph H. Hruban4,9, Drew M. Pardoll1, Barry S. Taylor11,12,13, David B. Solit13, Christine A Iacobuzio-Donahue2,11, and Suzanne L. Topalian5 From the 1Departments of Oncology, 3Dermatology, 4Pathology, 5Surgery, 6The Lowe Family Genomics Core, 8Oncology Bioinformatics Core, and the 9 Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287; the 10Laboratory of System Biology and Computational Genetics, Vavilov Institute of General Genetics, Russian Academy of Sciences, 119991, Moscow, Russia; and 2Pathology, 7Radiation Oncology, 11Human Oncology and Pathogenesis Program, 12Department of Epidemiology and Biostatistics, and the 13Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York NY 10065. MLA, AM-M, EJL, and JMT contributed equally to this work Running title: Transcriptional mechanisms of resistance to anti-PD-1 Key Words: melanoma, cancer genetics, immunotherapy, anti-PD-1 Financial Support: This study was supported by the Melanoma Research Alliance (to SLT and CI-D), the Bloomberg~Kimmel Institute for Cancer Immunotherapy (to JMT, DMP, and SLT), the Barney Family Foundation (to SLT), Moving for Melanoma of Delaware (to SLT), the 1 Downloaded from clincancerres.aacrjournals.org on October 2, 2021.
    [Show full text]
  • Type of the Paper (Article
    Cancers 2020, 12, S1 of S11 Supplementary Materials: Inflammatory Proteins HMGA2 and PRTN3 as Drivers of Vulvar Squamous Cell Carcinoma Pro- gression Agnieszka Fatalska, Natalia Rusetska, Elwira Bakuła-Zalewska, Artur Kowalik, Sebastian Zięba, Agnieszka Wroblewska, Kamil Zalewski, Krzysztof Goryca, Dominik Domański and Magdalena Kowalewska Text S1: Supplementary Methods iTRAQ (Isobaric Tags for Relative and Absolute Quantitation) Cell Lysis The samples were snap-frozen in liquid nitrogen immediately after collection and stored at −70°C before pulverization (with the Microdismembrator II, B Braun Biotech In- ternational, Melsungen, Germany). Forty-two (14 control, 16 d-fVSCC and 12 progVSCC) samples were subjected to deep proteomic analysis. Total cell lysates were obtained from approximately 100 mg of pulverized patient tissue samples. The frozen pulverized tissue samples were resuspended in 300 µl of cold Lysis Buffer (1% sodium deoxycholate (NaDOC) in 25 mM HEPES (4-(2-hydroxyethyl)-1-pipera- zineethanesulfonic acid), boiled for 5 min at 100 °C, and cooled to room temperature (RT) on ice. Next, nucleic acids were degraded with 30 µL of benzonase nuclease (2.5 U/µL in 25 mM HEPES) at 4 °C for 30 min. Samples were then centrifuged twice at 12,000 × g for 10 min at 4 °C and the supernatants were stored at −80 °C. Protein concentrations were determined using the Pierce (Appleton, WI, USA) Bicinchoninic Acid (BCA) Assay Kit according to the manufacturer’s instructions, for the 96-well plate format, in duplicate, at two different sample dilutions (ThermoFisher Scientific, Waltham, MA, USA). Sample Protein Extract Digestion and iTRAQ Labeling Protein extract digestion and iTRAQ tag labeling was conducted using the 8-plex iTRAQ assay and iTRAQ Reagent and Buffer Kits (AB SCIEX, Framingham, MA, USA).
    [Show full text]
  • Study for Pathogenesis of Congenital Cholesteatoma with Comparison of Proteins Expressed in Congenital Cholesteatoma, Acquired C
    Study for pathogenesis of congenital cholesteatoma with comparison of proteins expressed in congenital cholesteatoma, acquired cholesteatoma and skin of the external auditory canal through proteomics Seung Ho Shin Department of Medicine The Graduate School, Yonsei University Study for pathogenesis of congenital cholesteatoma with comparison of proteins expressed in congenital cholesteatoma, acquired cholesteatoma and skin of the external auditory canal through proteomics Directed by Professor Jae Young Choi The Doctoral Dissertation submitted to the Department of Medicine, the Graduate School of Yonsei University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Seung Ho Shin June 2014 ACKNOWLEDGEMENTS In the initial period of my fellowship, I wrote a book, Temporal Bone Dissection Manual as a coauthor with Professor Won Sang Lee, Ho-Ki Lee and Jae Young Choi. Through this book, I learned about much knowledge from them. Professor Jae Young Choi advised me to go for a Ph.D. I admitted graduate school for a Ph.D. in 2007. In my doctoral course, he has instructed me in detail on the basic research. He has demonstrated precise and delicate laboratory techniques and showed outstanding ability to create new ideas. Also, he has often said to me that a researcher must be honest to his colleagues and even to himself. After the summer of 2013, he gave me an idea for this paper, which was for congenital cholesteatoma analysis with proteomics. He always displayed endless energy and enthusiasm for scientific experiments even after many demanding surgeries. His passion motivated me to follow suit and seven months of our work at last bore fruit.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0010974A1 Milligan Et Al
    US 20050010974A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0010974A1 Milligan et al. (43) Pub. Date: Jan. 13, 2005 (54) PROMOTERS FOR REGULATION OF GENE Publication Classification EXPRESSION IN PLANT ROOTS (51) Int. Cl." ............................ C12N 15/82; C12O 1/68; (76) Inventors: Stephen B Milligan, Kirkland, WA C12N 15/87; C12N 15/63; (US); Dale Skalla, Research Triangle C12N 15/85; C12N 5/10; Park, NC (US); Kay Lawton, Research C12N 15/09; CO7H 21/04 Triangle Park, NC (US) (52) U.S. Cl. ..................... 800/287; 536/23.6; 435/320.1; 435/455; 435/419; 435/468; Correspondence Address: 800/278; 435/6; 536/24.33 Randee S Schwatz Syngenta Biotechnology 3054 Cornwallis Road (57) ABSTRACT Research Triangle Park, NC 27709 (US) The present invention is directed to promoters isolated from (21) Appl. No.: 10/490,147 maize and functional equivalents thereto. The promoters of the present invention have particular utility in driving root (22) PCT Filed: Nov. 4, 2002 Specific expression of heterologous genes that impart (86) PCT No.: PCT/US02/35374 increased agronomic, horticultural and/or pesticidal charac teristics to a given promoters of the invention and trans (30) Foreign Application Priority Data formed plant tissues containing DNA molecules comprising a promoter of the invention operably linked to a heterolo Nov. 7, 2001 (US)........................................... 60337026 gous gene or genes, and Seeds thereof. US 2005/0010974 A1 Jan. 13, 2005 PROMOTERS FOR REGULATION OF GENE latory Sequences may be short regions of DNA sequence EXPRESSION IN PLANT ROOTS 6-100 base pairs that define the binding sites for trans-acting factors, Such as transcription factors.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Downloaded and Searched Against the Dbest Database to Identify Ests
    BMC Genomics BioMed Central Research article Open Access A transcription map of the 6p22.3 reading disability locus identifying candidate genes Eric R Londin1, Haiying Meng2 and Jeffrey R Gruen*2 Address: 1Graduate Program in Genetics, State University of New York at Stony Brook, NY, USA and 2Yale Child Health Research Center, Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA Email: Eric R Londin - [email protected]; Haiying Meng - [email protected]; Jeffrey R Gruen* - [email protected] * Corresponding author Published: 30 June 2003 Received: 22 April 2003 Accepted: 30 June 2003 BMC Genomics 2003, 4:25 This article is available from: http://www.biomedcentral.com/1471-2164/4/25 © 2003 Londin et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. reading disabilitydyslexia6p22.3In silicoESTs Abstract Background: Reading disability (RD) is a common syndrome with a large genetic component. Chromosome 6 has been identified in several linkage studies as playing a significant role. A more recent study identified a peak of transmission disequilibrium to marker JA04 (G72384) on chromosome 6p22.3, suggesting that a gene is located near this marker. Results: In silico cloning was used to identify possible candidate genes located near the JA04 marker. The 2 million base pairs of sequence surrounding JA04 was downloaded and searched against the dbEST database to identify ESTs. In total, 623 ESTs from 80 different tissues were identified and assembled into 153 putative coding regions from 19 genes and 2 pseudogenes encoded near JA04.
    [Show full text]